Kayla Mehlhaf
Family · Viborg, SDNPI 1154681880
Payments from drug & device makers
Across 101 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$310
- Pfizer$243
- Bayer$177
- Amgen$121
- Novo Nordisk$111
- Johnson & Johnson$94
- plus $614 from 18 others
What the payments were for
- Food & beverage$1,65999%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols USA, LLC | 18 | $310 |
| Pfizer | 16 | $243 |
| Bayer | 11 | $177 |
| Amgen | 8 | $121 |
| Novo Nordisk | 7 | $111 |
| Johnson & Johnson | 5 | $94 |
| Lilly USA, LLC | 4 | $65 |
| Boehringer Ingelheim | 4 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $55 |
| Organon | 2 | $54 |
| Vanda Pharmaceuticals Inc. | 2 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Medtronic | 2 | $36 |
| Mylan Specialty L.p. | 2 | $33 |
| Novartis | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Baxter Healthcare | 1 | $20 |
| AbbVie | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Merck | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
| AstraZeneca | 1 | $12 |
How this compares
$1,670 in reported general payments places this provider in the 85th percentile of 588 family providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 48 | $67,442 |
| JardianceEmpagliflozin | 47 | $46,969 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 22 | $44,646 |
| EliquisApixaban | 53 | $41,778 |
| XareltoRivaroxaban | 30 | $35,545 |
| MounjaroTirzepatide | 33 | $33,419 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $20,684 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $12,655 |
| MyrbetriqMirabegron | 18 | $10,737 |
| KerendiaFinerenone | 12 | $9,940 |
| FarxigaDapagliflozin Propanediol | 16 | $8,870 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $4,581 |
| Fentanyl | 24 | $3,205 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $3,167 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $2,570 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $111 | $67,44248 claims |
| Boehringer IngelheimJardiance | $61 | $46,96947 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $37 | $44,64622 claims |
| PfizerEliquis | $243 | $41,77853 claims |
| Johnson & JohnsonXarelto | $94 | $35,54530 claims |
| Lilly USA, LLCMounjaro | $65 | $33,41933 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $10,73718 claims |
| BayerKerendia | $177 | $9,94012 claims |
| AstraZenecaFarxiga | $12 | $8,87016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 588 family providers in South Dakota.
Other family in Viborg
- Brittany WangsnessSioux Falls$79K
- Stephanie PreisterSioux Falls$12K
- Claudia HouglandRapid City$9K
- Maria AzpeitiaDakota Dunes$8K
- Michelle VanhoveSioux Falls$7K
- Sandra EricksonHerreid$7K
- Melissa OwensRapid City$6K
- Heidi FurthSioux Falls$6K
- Tabitha AmmannSioux Falls$6K
- Michelle BrandenburgHuron$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.